STERO aims to solve an unmet need by using Cannabidiol (CBD), a non-psychotropic component of Cannabis sativa, which has been shown to possess potent immunomodulatory and anti-inflammatory properties in various indications.

Our preliminary results in a phase II trial in GVHD show that CBD administration enhanced the therapeutic effect of steroids or reduced the steroid dosage while maintaining or improving the steroid’s original therapeutic effect.

In all patients treated, the steroid dose administered with CBD was gradually decreased over time. patients refractory to steroid treatment also presented significant improvement to the CBD treatment.

The company plans to validate its concept in various autoimmune diseases.
The company’s first product ST-101 is targeted for AutoImmune Hepatitis, an orphan autoimmune liver disease which requires long-term steroid treatment as immunosuppressive medication. A phase IIa clinical trial has started on May 2019.

The company’s second product is targeted for Crohn’s disease, an inflammatory bowel disease (IBD).
A phase IIa clinical trial started on July 2019.

Other indication is planned for 2019 and more in the pipeline.